What is the BMS-2000 Patent for Dasatinib?
The BMS-2000 patent, officially U.S. Patent No. 7,470,704, covers dasatinib, a tyrosine kinase inhibitor used to treat certain types of leukemia. This patent was filed by Bristol-Myers Squibb (BMS) and is a key piece of intellectual property protecting the drug [1].
When Does the Dasatinib Patent Expire?
The U.S. Patent No. 7,470,704 for dasatinib is set to expire on March 28, 2027 [1]. This expiration date is crucial for understanding when generic versions of the drug may become available.
Are There Other Patents Protecting Dasatinib?
Beyond U.S. Patent No. 7,470,704, Bristol-Myers Squibb holds several other patents related to dasatinib. These can include patents covering the drug's formulation, manufacturing processes, and methods of use, potentially extending market exclusivity beyond the expiry of the primary patent [2]. DrugPatentWatch.com tracks these various patent protections and their expiry dates [2].
Why Are Companies Challenging the Dasatinib Patent?
Generic drug manufacturers often challenge existing patents to pave the way for their own product launches. Challenges can involve arguing that the patent is invalid, that their product does not infringe the patent, or that the patent is unenforceable. Successful challenges can lead to earlier market entry for generic alternatives [3].
How Does Dasatinib Work?
Dasatinib is a small molecule inhibitor that targets specific tyrosine kinases, including BCR-ABL and SRC family kinases. By inhibiting these enzymes, it disrupts the signaling pathways that drive the growth of cancer cells, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4].
What are the Clinical Uses of Dasatinib?
Dasatinib is prescribed for adults with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, as well as for patients with CML in chronic, accelerated, or blast phase who are resistant or intolerant to prior therapy. It is also used for adults with Ph+ ALL who are resistant or intolerant to prior therapy [4].
How Does Dasatinib Compare to Other Leukemia Treatments?
Dasatinib is one of several tyrosine kinase inhibitors (TKIs) available for CML and Ph+ ALL. Other TKIs include imatinib (Gleevec), nilotinib (Tasigna), bosutinib (Bosulif), and ponatinib (Iclusig). The choice of TKI often depends on factors such as the specific mutation, patient tolerability, and prior treatment history [5].
What is the Patient Impact of Generic Dasatinib Availability?
The expiration of patents for brand-name drugs like dasatinib typically leads to the introduction of lower-cost generic versions. This increased competition can significantly reduce drug prices, improving access and affordability for patients undergoing treatment [3].